Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Investigating GSTP1 as a novel regulator of the cysteine redoxome in breast cancer and maker of vulnerability to redox-based therapy

Award Number: R21CA270876
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/12/2022
PERIOD OF PERFORMANCE END DATE: 11/30/2025

Group Awards By:

View Award Description

Investigating GSTP1 as a novel regulator of the cysteine redoxome in breast cancer and maker of vulnerability to redox-based therapy - Project Summary Glutathione S-transferase Pi 1 (GSTP1) is an enzyme that conjugates glutathione to small molecule electrophiles. GSTP1 has been implicated in promoting the growth of many cancer types where GSTP1 overexpression is proposed to promote metabolic re-wiring or sequester cancer-related signaling proteins through protein-protein interactions. In contrast to the modest upregulation of GSTP1 in cancer reported by these studies, our systematic evaluation of cancer cell lines, patient-derived xenografts, and patient tumors finds that GSTP1 expression is uniquely and dramatically silenced by many orders of magnitude in luminal breast cancer, going from one of the most abundant cellular proteins to barely express. Her2 positive (Her2+) breast cancers have a bimodal GSTP1 expression distribution, with a significant proportion also silencing GSTP1. Decreased GSTP1 expression in breast cancer allowed us to discover a novel, non-canonical regulatory function of GSTP1: re-directing the flux of cysteine oxidation to structurally remodel the proteome via allosteric disulfide bonds. These changes are critical for breast cancer transformation since re-expression of GSTP1 and inhibition of redox signaling decreases the transformation capacity of GSTP1-silenced breast cancer cells. This proposal focuses on two Specific Aims. First, is GSTP1 silencing a therapeutic vulnerability in BRCA? Second, what are the molecular and redoxomic consequences of GSTP1 silencing? Together, these Aims will provide new mechanistic insight into how GSTP1 expression drives redox signaling in breast cancer and determine if GSTP1 silencing is a therapeutically actionable vulnerability.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$87,719 )
2026	2024	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Treatment Research	000	2	3/26/2026	NON-COMPETING CONTINUATION	-$87,719
														Subtotal = -$87,719

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Treatment Research	000	2	1/10/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $207,185 )
2024	2024	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Cancer Treatment Research	001	2	4/24/2024	NON-COMPETING CONTINUATION	$10,905
2024	2024	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Cancer Treatment Research	000	2	11/29/2023	NON-COMPETING CONTINUATION	$196,280
														Subtotal = $207,185

Issue Date FY: 2023 ( Subtotal = $183,104 )
2023	2023	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Treatment Research	000	1	12/12/2022	NEW	$183,104
														Subtotal = $183,104

Grand Total All Awards = $302,570

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Investigating GSTP1 as a novel regulator of the cysteine redoxome in breast cancer and maker of vulnerability to redox-based therapy

Award Number: R21CA270876

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/12/2022

PERIOD OF PERFORMANCE END DATE: 11/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer